✦ LIBER ✦

Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Lung Adenocarcinoma: Results of a Nagano Lung Cancer Research Group Study

✍ Scribed by Kazuhiro Asami; Tomonobu Koizumi; Kazuya Hirai; Shingo Ameshima; Akihiro Tsukadaira; Nobutoshi Morozumi; Akio Morikawa; Shinji Atagi; Masaaki Kawahara

Book ID: 113544730
Publisher: CIG Media Group, LP.
Year: 2011
Tongue: English
Weight: 308 KB
Volume: 12
Category: Article
ISSN: 1525-7304
DOI: 10.1016/j.cllc.2011.02.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical outcomes in elderly patients ad

Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group Study

✍ Kazunari Tateishi, Takashi Ichiyama, Kazuya Hirai, Toshihiko Agatsuma, Shigeru K 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 230 KB

Cost-effectiveness of epidermal growth f

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung

✍ Gilberto de Lima Lopes Jr.; Joel E. Segel; Daniel S. W. Tan; Young K. Do; Tony M 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 870 KB

## Abstract ## BACKGROUND: Epidermal growth factor receptor (EGFR) testing and first‐line therapy with gefitinib for patients with activating mutations is quickly becoming the standard option for the treatment of advanced lung adenocarcinoma. Yet, to date, little is known about the cost‐effectiven

Gefitinib as first-line treatment for pa

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence

✍ Gridelli, C.; De Marinis, F.; Di Maio, M.; Cortinovis, D.; Cappuzzo, F.; Mok, T. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 216 KB

Gefitinib as first-line treatment for pa

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues

✍ Gridelli, C.; De Marinis, F.; Di Maio, M.; Cortinovis, D.; Cappuzzo, F.; Mok, T. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 144 KB

OP3 Cost-effectiveness of epidermal grow

OP3 Cost-effectiveness of epidermal growth-factor receptor mutation testing and first-line treatment with gefitinib for advanced non-small-cell lung cancer

✍ G. de Lima Lopes; J. Segel; D. Tan; Y. Do; T. Mok; E. Finkelstein 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 34 KB

PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (

PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

✍ G. de Lima Lopes 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB